Shareholders Equity: The sum of preferred and common equity items.
MoonLake Immunotherapeutics (MLTX) had Shareholders Equity of $304.48M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-62.42M |
|
-- |
|
-- |
|
$65.22M |
|
$-65.22M |
|
$2.45M |
|
$-62.77M |
|
$-62.77M |
|
$-63.02M |
|
$-63.02M |
|
$-63.02M |
|
$-63.02M |
|
$-65.22M |
|
$-64.47M |
|
64.46M |
|
64.46M |
|
$-0.93 |
|
$-0.93 |
|
| Balance Sheet Financials | |
$421.69M |
|
$0.58M |
|
$2.74M |
|
$424.43M |
|
$45.48M |
|
$74.10M |
|
$74.47M |
|
$119.95M |
|
$304.48M |
|
$304.48M |
|
|
Shareholders Equity |
$304.48M |
71.37M |
|
| Cash Flow Statement Financials | |
$-196.01M |
|
$202.99M |
|
$146.00M |
|
$180.43M |
|
$334.52M |
|
$154.09M |
|
$12.90M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.27 |
|
-- |
|
-- |
|
0.20 |
|
0.24 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-196.04M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.70% |
|
-20.70% |
|
-14.85% |
|
-16.65% |
|
$4.27 |
|
$-3.04 |
|
$-3.04 |
|